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Summary We have investigated the use ofthe antibody MIBl as a proliferative and prognostic marker in breast cancer and whetherchanges
in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the
menstrual cycle. MIBl expression was strongly correlated with S-phase fraction and histological grade. There was no difference in MIBl
scores between different phases of the menstrual cycle. Both MIBl score and timing of surgery correlated significantly with duration of
survival, while the two together were even stronger predictors of overall survival. Women with slowly proliferating tumourssurgically removed
in the luteal phase had a very good prognosis, whereas women with rapidly proliferating tumours excised at other times of the cycle had a
worse prognosis.
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Numerous studies have shown that the measurement of tumour
cell proliferative activity can be used to predict the clinical
outcome of patients with breast cancer (van Dierendonk et al,
1989; Wintzer et al, 1991). However, many of the methods
described for measuring proliferative activity are unsuitable for
routine use. The most objective way ofmeasuring proliferation in
histopathological material is by flow cytometry, which measures
DNA content and allows calculation ofthe percentage ofcells in S
phase. However, for flow cytometry to be carried out on paraffin-
processed tissue, a substantial amount of tissue has to be cut
from the block, which precludes its use on small tumours.
Immunohistochemical assessment of proliferative activity has the
potential to overcome many ofthe problems associated with other
methods, and the recent introduction of heat-mediated antigen
retrieval techniques to expose antibody binding sites has enhanced
the use of immunohistochemistry for measuring proliferation
(Bankfalvi 1994; Norton et al, 1994).
Several cell cycle-regulating proteins can be demonstrated by
immunohistochemistry, and one of the first antibodies to be devel-
oped for this purpose was monoclonal Ki-67, which selectively
demonstrates the nuclei ofproliferating cells (Gerdes et al, 1983). A
numberofstudies have found an association between Ki-67 expres-
sion and otherprognostic variables (Walker and Camplejohn, 1988;
Wintzer et al, 1991). Until recently, the most significant limitation
to the use ofmonoclonal Ki-67 was the need for frozen material, as
the antigen is very sensitive to fixation and prolonged storage
(Neubauer and Hunn, 1987). However, the monoclonal antibody,
MIB1, has now been developed, and this has the advantage of
recognizing part ofthe Ki-67 protein in fixed tissue (Cattoretti et al,
1992). Confirmation of similar staining patterns ofmonoclonal Ki-
67 on frozen tissue and MIB1 on fixed tissue have been obtained
(Weidner et al, 1994; Veronese et al, 1996).
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To be clinically useful, MIB1 staining needs to reflect accu-
rately the tumours' proliferative activity. In the present
study, proliferative activity of breast cancer tissue measured by
MIB1 staining was compared with flow cytometry to assess the
accuracy of this immunohistochemical method for determining
proliferation.
It has been suggested that the timing of surgery affects prog-
nosis in premenopausal patients (Hrushesky et al, 1989) and
previous studies undertaken at Guy's Hospital have shown that
women who have their surgery during the follicular phase (days
3-12) have a poorer prognosis than those women operated on
during the luteal phase (days 0-2, 13-32) of the menstrual cycle
(Badwe et al, 1991a,b).
There have been a number of suggestions as to the mechanism
involved in the differences in prognosis (Badwe et al, 1995; Oliver
and Ingram, 1995; Perren, 1995; von Minckwitz et al, 1995), but
the influence of proliferative activity during the luteal and follic-
ular phases has not been investigated. Proliferative activity of
breast epithelium naturally fluctuates during the cycle in response
to both oestrogen and progesterone. Studies have shown an
increase in the number of mitoses during the second half of the
cycle (Anderson et al, 1981; Ferguson and Anderson, 1981).
Oestrogen has a known promoting influence on breast cancer
progression (Hawkins, 1985). Consequently, there is considerable
interest in the effect on proliferative activity of varying hormone
levels throughout the menstrual cycle.
For this reason, MIB1 has been used to examine the prolifera-
tive activity of tumours from a group of premenopausal patients
for whom the day oftheir menstrual cycle on which they had their
biopsy was known.
MATERIALS AND METHODS
The 119 patients in this study were a subset of patients from the
original Guy's study (Badwe et al, 1991a) and were diagnosed and
treated for primary infiltrating mammary carcinoma at the
Imperial Cancer Research Fund's Clinical Oncology Unit at Guy's
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Figure 1 Immunohistochemical staining of sections from a primary breast
carcinoma using the proliferation antibody MIBl showing (A) a high MIBl
score and (B) a low MIBl score
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Figure 2 The relationship between MIBl score and S-phase fraction (SPF)
in 64 primary breast tumours (r, = 0.453, P < 0.001)
Hospital between 1975 and 1985. Long-term verified follow-up
data were available for all women. All patients were
premenopausal, and the date of their last menstrual period (LMP)
before surgery was known. Hence, the day oftheir menstrual cycle
on which they had their operation was calculated. S-phase fraction
(SPF) was determined by flow cytometry on 64 of the cases that
had suitable tumour material available.
The clinical size ofthe tumours was known, and the histological
type was established by using guidelines from the World Health
Organization (1982). There were two main histological types of
breast cancer, infiltrating ductal carcinoma of no special type and
infiltrating lobular carcinoma. Histological grade was determined
by the modified Bloom and Richardson systemproposedby Elston
and Ellis (1991). The number of tumour-containing lymph nodes
from axillary dissections and the microscopic tumour size were all
determined by Dr Rosemary Millis, the consultant pathologist at
that time. The flow cytometry was carried out by Dr Richard
Camplejohn at the Richard Dimbleby Department of Cancer
Research, St Thomas' Hospital, London.
Immunohistochemical methods
Dewaxed and rehydrated 3 ,um sections from the primary tumours
of the selected patients were microwaved in 0.01 M citrate buffer,
pH 6.0, for 30 min and stained with MIB1 (kindly provided by J
Gerdes) at a 1:300 dilution, using a standard peroxidase-conju-
gated streptavidin-biotin complex method, visualized with
diaminobenzidine (DAB; Sigma, UK) and lightly counterstained
with haematoxylin. The primary antibody was omitted and
replaced with phosphate-buffered saline on sections used as nega-
tive controls, and a section ofnormal tonsil was included as aposi-
tive control for proliferating cells.
Evaluation of MIB1 immunostaining was carried out within an
area with a high degree of cellularity. All malignant cells with
nuclear staining of any intensity were regarded as positive. A
10 x 10 G14-21 mm soil analysis graticule (Graticules Ltd, UK)
was used to aid the counting ofthe total number ofmalignant cells
and the number of stained malignant cells within one high-power
field (x400, 1.19 mm2). Adjacent fields were assessed, and at least
1000 malignant cells were counted per slide. Proliferative activity
was assessed as the percentage ofMIB1-stained cells in the sample.
Statistical methods
MIB1 score was compared with SPF and day of menstrual cycle
using Pearson's product moment correlation coefficient.
Univariate analysis (chi-square and Fisher's exact test) was carried
out to compare MIB1 score with established prognostic markers:
SPF, nodal status, tumour size, tumour type and grade, age of
patient and LMP. Multivariate analysis (Cox, 1972) was used to
determine associations between the different prognostic factors
and to ascertain their independent ability to predict prognosis.
Survival curves were generated using log-rank analysis, directly
comparing MIB1 staining with overall survival (Peto et al, 1977).
RESULTS
The 119 patients selected for this study showed similar character-
istics to a representative group of premenopausal patients treated
in our unit with the exception of tumour size. This difference is
explained by the fact that half of the cases were selected because
the tumours were sufficiently large to allow flow cytometry to be
carried out. The proliferative activity determined by this method of
measurement was compared with MIB1 staining to establish the
accuracy ofMIB1 immunohistochemistry as a marker ofprolifera-
tion in our material.
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Table 1 Association between MIBl score and established prognostic markers
Age
Mean 43 years
MIBl score
Mean 10.56%
Histological type
Infiltrating ductal grade
Infiltrating ductal grade 11
Infiltrating ductal grade IlIl
Infiltrating lobular
Others
Range 24-53 years
Range 0.5-73%
Total
13
45
35
13
13
MIBl < 10%
9 (69%)
25 (56%)
5 (14%)
9 (69%)
8 (62%)
Histological grade
(including invasive ductal,
lobular and special types)
Grade
Grade II
Grade IlIl
Unknown
Nodal status
Total
20
55
41
3
MIBI < 10%
13 (65%)
34 (621%)
7 (17%)
2 (67%)
MIBl > 10%
4 (31%)
20 (44%)
30 (86%)
4 (31%)
5 (38%)
MIBI > 10%
7 (35%)
21 (38%)
34 (83%)
1 (33%)
X2 = 22.62, P= 0.0002
(infiltrating ductal vs lobular)
2= 22.21, P< 0.0001
X2=4.22, P=0.04
%2 = 0.03, P= 0.88
Table 2 Association between MIBl score and phase of menstrual cycle
Days
0-2 and 13-32 3-12
(luteal phase) (follicular phase)
LMP phase 'Good' 'Bad'
No. of cases 62 57
MIBl score
< 10% 32 (52%) 24 (42%)
> 10% 30 (48%) 33 (58%) X2 = 0-73. p = 0.4
Proliferative activity, determined by MIB1 score, was consid-
ered 'high' if more than 10% ofthe cells were positive and 'low' if
10% or less were positive. This cut-off point was used because it
was closest to the median MIB 1 score. Examples of high and low
proliferating tumours are illustrated in Figure IA and B.
When MIB 1 was compared with SPF in the 64 cases with avail-
able data, there was a significant correlation between the two when
evaluated as continuous variables (r = 0.45, P < 0.001, Figure 2).
However, this significance was lost when both were divided into
high and low proliferative activity groups (X2 = 3.39, P = 0.065).
Table 1 shows the relationship between MIB I score and estab-
lished prognostic markers. There were highly significant associa-
tions between MIB 1 score and histological type (X2 = 22.62,
P < 0.0001) as well as histological grade (X2 = 22.21, P < 0.0001).
There was a weak association with nodal status (%2 = 4.22,
P = 0.04) but no association with tumour size.
There was no significant difference in the proportion of high
and low proliferative tumours distributed between the two phases
of the menstrual cycle (Table 2), nor any significant relationship
between proliferative activity and timing of surgery (Figure 3).
The prognostic significance of high and low proliferative
activity is shown in Figure 4. Patients with a MIB1 score of 10%
or less had a longer survival time than those with a score of more
than 10% (%2 = 17.26, P < 0.001). At 10 years, over 80% of the
patients with slowly proliferating cancers were still alive,
compared with less than 50% of those with rapidly proliferating
tumours. Surprisingly, among the patients in the high proliferative
activity group, the degree of proliferation had no effect on the
duration of their survival, which was similar for patients with a
MIB I score of 10-20% or more than 20%.
When overall survival ofthe two LMP groups was compared, a
significant difference was found (%2 = 17.45, P < 0.001). Patients
who had their operations during days 3-12 of the menstrual cycle
had a poorer outcome, with only 45% ofpatients being alive at 10
years compared with 75% ofpatients operated on during the luteal
phase (Figure 5).
The combined effect of MIB1 score and time of surgery was
able to predict significantly the overall survival of the patients in
this study (%2 = 31.52, P < 0.001, Figure 6). Women with a slowly
proliferating tumour removed in the luteal (good) phase of the
menstrual cycle had a very good prognosis, with a 10-year survival
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Negative
Positive
Tumour size
Total
53
66
<2 cm
>2cm
MIBI < 10%
31(58%)
25 (38%)
MIBl < 10%
21 (49%)
34 (45%)
Total
43
75
MIBI > 10%
22 (42%)
41 (62%)
MIBl > 10%
22 (51%)
41 (55%)
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Figure 3 The relationship between MIBl score and timing of surgery
(r, = -0.140, P = 0.065) in 119 patients
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Figure 4 Overall survival of patients with a high and low tumour
proliferative activity denoted by the MIBl score (X2 = 17.26, P < 0.001)
Figure 5 Overall survival of patients who had their operations during the
luteal (good) phase of their menstrual cycle compared with patients operated
on during their follicular (bad) phase (X2 = 17.45, P < 0.001)
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Figure 6 Overall survival of patients in whom both the timing of surgery
and the proliferative activity of their primary tumour are taken into account
(X2 = 31.52, P < 0.001)
Table 3 Univariate and multivariate analysis of MIBl compared with other clinicopathological parameters
Univariate Multivariate
Variable P2 Pvalue RR' 95%Cb X2 P-value RR 95% Clib
T. of S.c 17.12 < 0.0001 3.23 1.81-5.75 17.34 < 0.0001 3.17 1.74-5.77
Nodal statusd 19.97 <0.0001 1.82 1.41-2.33 13.38 0.0003 1.68 1.29-2.20
Tumour sizee 9.59 0.0021 1.34 1.13-1.6 5.49 0.02 1.26 1.05-1.50
Grade' 10.66 0.0011 1.96 1.29-2.97 16.44 0.0001 1.84 1.17-2.89
MIBli 14.58 0.0001 1.04 1.02-1.06 4.59 0.03 1.03 1.01-1.05
aRelative risk; b95% confidence interval; ctiming of surgery: days 3-12 vs all other days; dnode-negative vs 1-3 vs4-9 vs 2 10 positive nodes; ehistological grade
vs grade 11 vs grade ll; 'tumour size and MIBl staining treated as continuous variables.
of over 90%. For the patients with either a slow proliferating
tumour surgically removed during the follicular (bad) phase or a
rapidly proliferating tumour excised in the luteal phase, the prog-
nosis was similar, with a 10-year survival of 60%. The women
with the worst outcome were those with rapidly proliferating
tumours removed during the follicular phase. Their 10-year
survival was only 30%. A similar outcome was seen when the
combined effect of grade and phase of cycle was used to predict
overall survival (x2 = 32.97, P < 0.001).
In a Cox model analysis to investigate the relationship between
prognostic markers and outcome on the complete study group,
univariate analysis showed that nodal status, timing of surgery,
histological grade, tumour size and MIB1 score were indepen-
dently significant (Table 3). The best predictor was nodal status
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(x2 = 19.97) followedby timing of surgery (x2 = 17.12) and MIBI
staining (X2=14.58). When these prognostic markers were entered
into a multivariate analysis, timing ofsurgery was the most impor-
tant predictor of overall survival (%2 = 17.34) (Table 3). This was
followed by histological grade (X2 = 16.44), nodal status (X2 =
13.38), tumour size (X2 = 5.49) and MIBI staining (X2 = 4.59). The
close relationship between histological grade and MIB1 staining is
demonstrated by the fact that, when grade is left out of the model,
the information provided by MIB1 score is highly significant (X2 =
13.62, P = 0.0002). In the subgroup of 64 patients for whom SPF
data was available, MIB1 lost its independent significance because
ofits close association with SPF.
DISCUSSION
S-phase fraction determined by flow cytometry is considered one
of the most objective methods ofmeasuring proliferative activity.
However, it is an inappropriate method for small or unusual
tumours and is a facility not generally available to the pathologist.
The proliferation-associated antigen Ki-67, which can be detected
by immunohistochemisty using the monoclonal antibody MIB1, is
one of a number of antigens whose expression during specific
phases ofthe cell cycle has enabled them to be termed 'markers of
proliferative activity'. It has also been reported that MIB1 staining
is associated with other known prognostic factors in breast cancer
and with overall survival (Pinder et al, 1995).
In the subset ofpatients with SPF data, we have shown that the
proportion of MIB1-labelled cells is significantly associated with
SPF. It was impossible to extend the comparison to the whole
series because ofeither insufficient material or technical problems
but, in view of our results on the 64 cases and the association
between SPF and histological grade already established for our
samples (O'Reilly et al, 1990), we considered that the number of
cases with results by both methods was sufficient to confirm MIB1
immunohistochemistry as a good marker of proliferative activity.
Others have confirmed this finding and also shown that MIBI is
strongly associated with otherrecognized markers ofproliferation,
including mitotic count and Ki-67 expression (Lipponen et al,
1992; McCormick et al, 1993; Ellis et al, 1996).
MIB1 immunohistochemistry is easier to perform than flow
cytometry and quicker to evaluate than mitotic index. In this study,
we used a cut-off point of 10% to distinguish between high and
low MIB1 scores, because this value is close to the median as well
as being the value used in many Ki-67 studies. The present study
shows that MIB1 scores are significantly associated with tumour
grade, and this association could make MIB1 staining useful in a
diagnostic laboratory. Counting MIB1-stained cells is a simple
process, which could perhaps be less ambiguous and subjective
than grading breast tumours and, if it were shown to be more
consistent, MIB1 staining could become a useful alternative to
grading tumours. Hence, the knowledge ofproliferative activity of
breast tumours gained by the determination ofMIB1 scores could
influence the management ofpatients.
As with previous studies undertaken at our unit, we found that
patients who had their operation during days 3-12 of their
menstrual cycle had a worse prognosis than those who had tumour
excision at any other time. The patients used in the present study
were part of the original group in whom timing of surgery was
found to be of prognostic significance (Badwe et al, 1991a). The
relationship between operating time and the clinical course of the
disease has proved to be very controversial with many conflicting
results. Stonelake et al (1995) reported acompletely opposite asso-
ciation, with the 'good phase' occurring on days 3-12. Many
hospitals are reluctant to adopt the approach ofrescheduling oper-
ating times to accommodate the good phase ofthe menstrual cycle
as defined by our previous data because of the opposing results
that have been reported, and altering the timing ofsurgery to avoid
days 3-12 may actually put the patient at risk. However, a recent
meta-analysis of 21 published studies showed that timing of
surgery had a significant effect, with an average 16% increase in
overall survival in those operated on during the luteal phase ofthe
menstrual cycle (Fentiman et al, 1994). The importance of timing
ofbreast cancer surgery has been highlighted recently in an article
in theJournal oftheNational CancerInstitute, whichreported that
several centres have emphasized the need for a prospective study
(Anon. 1997).
In the original study from Guy's Hospital, the effect of
menstrual phase was of equal magnitude in patients with both
oestrogen receptor-positive and oestrogen receptor-negative
tumours (Badwe et al, 1991a). Similarly, a significant effect of
timing of surgery was seen in patients with both grade I/II and
grade III tumours, although oflesser magnitude in the latter group.
The present study shows that the measurement of proliferative
activity provides additional prognostic information to the effect of
timing of surgery. Among the patients operated on during the
follicular (bad) phase, two subgroups with different prognoses
could be identified according to their MIB1 score. The difference
between the 10-year survival of these groups is approximately
30%. Similarly, MIB1 score could identify two groups among
those operated on during the luteal (good) phase, who also had a
30% difference in survival.
Patients operated on in the follicular phase are assumed to have
unopposed circulating oestrogens, and those in the luteal phase
have either low or moderate levels ofoestrogen. It has been postu-
lated that more tumour cells are disseminated at operations under-
taken at times of high unopposed oestrogen levels, which, under
these conditions, are more able to proliferate and become estab-
lished as micrometastases. This study has shown that proliferation
of the primary tumour does not increase during the follicular
phase, nor does it follow the fluctuations seen in normal breast
epithelium during the menstrual cycle.
MIB1 staining is notonly agood markerofcellularproliferation
but also has prognostic value, being significantly associated with
overall survival. The degree of MIB1 staining was not associated
with the phase ofthe menstrual cycle. Hence, proliferative activity
does not appear to account for the differences in prognosis
according to timing ofsurgery.
Proliferative activity measured by MIB1 immunohistochemistry
is an important diagnostic tool, which may be a useful alternative
to histological grading. Staining with MIB1 is easy to perform and
may be used to predict the clinical course ofbreast cancer, thereby
helping to improve the management ofpatients with the disease.
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